QuantiFERON ® -TB Gold In-Tube test and tuberculin skin test in screening for latent tuberculosis in psoriasis

How to cite this article:
Tin SS, Wiwanitkit V. QuantiFERON ® -TB Gold In-Tube test and tuberculin skin test in screening for latent tuberculosis in psoriasis. Ann Trop Med Public Health 2015;8:74

 

How to cite this URL:
Tin SS, Wiwanitkit V. QuantiFERON ® -TB Gold In-Tube test and tuberculin skin test in screening for latent tuberculosis in psoriasis. Ann Trop Med Public Health [serial online] 2015 [cited 2020 Aug 7];8:74. Available from: https://www.atmph.org/text.asp?2015/8/3/74/157642

Dear Sir,

The usefulness of QuantiFERON-TB Gold In-Tube test (QFT-GIT) and tuberculin skin test (TST) for the screening of latent tuberculosis is interesting. The use of these two tests in the case of patients with some specific concomitant medical disorders should be discussed. Of several conditions, psoriasis is an interesting underlying problem to be considered. Although both QFT-GIT and TST for the screening of latent tuberculosis are widely assessed for their diagnostic properties, psoriasis is a complex immunologic disorder; therefore, it is not possible to project the results of other studies to a study population of psoriasis patients. Duman et al. concluded that “the cut-off point for TST positivity in psoriasis and PA patients should be re-evaluated, or other tests, such as the QFT-GIT, should be used.” [1] The conclusions of Duman et al. are pertinent for only those patients with psoriasis. In fact, as an interferon-gamma release assay, QFT-GIT is approved for its efficacy in the diagnosis of latent tuberculosis. [2] However, it should be noted that many reports did not show QFT-GIT as having better efficacy than the standard TST. [3],[4] Finally, the cost-effectiveness of QFT-GIT should also be discussed. It seems that the higher cost of QFT-GIT might be a big obstacle for using this test in resource-limited settings where tuberculosis is usually endemic. [5] Nevertheless, there is not enough literature regarding the costs in case of psoriasis patients. In some cases, antitumor necrosis factor (anti-TNF) agents are used and in case of false negative TST, the cost will increase if the patient dies or if there is a need for tuberculosis treatment.

References

 

1.
Duman N, Ersoy-Evans S, Karadağ O, Aşçıoğlu S, Sener B, Kiraz S, et al. Screening for latent tuberculosis infection in psoriasis and psoriatic arthritis patients in a tuberculosis-endemic country: A comparison of the QuantiFERON ® -TB Gold In-Tube test and tuberculin skin test. Int J Dermatol 2014;53:1286-92.
2.
De Keyser E, De Keyser F, De Baets F. Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection. Acta Clin Belg 2014;69:358-66.
3.
Verhagen LM, Maes M, Villalba JA, d’Alessandro A, Rodriguez LP, España MF, et al. Agreement between QuantiFERON ® -TB Gold In-Tube and the tuberculin skin test and predictors of positive test results in Warao Amerindian pediatric tuberculosis contacts. BMC Infect Dis 2014;14:383.
4.
Rutherford ME, Nataprawira M, Yulita I, Apriani L, Maharani W, van Crevel R, et al. QuantiFERON ® -TB Gold In-Tube assay vs. tuberculin skin test in Indonesian children living with a tuberculosis case. Int J Tuberc Lung Dis 2012;16:496-502.
5.
Wiwanitkit V. Field QuantiFERON-TB gold test. Am J Infect Control 2011;39:447.

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/1755-6783.157642

Paul Mies has now been involved with test reports and comparing products for a decade. He is a highly sought-after specialist in these areas as well as in general health and nutrition advice. With this expertise and the team behind atmph.org, they test, compare and report on all sought-after products on the Internet around the topics of health, slimming, beauty and more. The results are ultimately summarized and disclosed to readers.

LEAVE A REPLY

Please enter your comment!
Please enter your name here